-
Falcon confirms rat Sstr5 (P30938) is a class A/rhodopsin-like 7TM GPCR of the somatostatin receptor family that mediates the inhibitory actions of the somatostatin neuropeptide.
"Somatostatin receptors (SSTR1–5) are **class A/rhodopsin-like GPCRs** with a **canonical 7TM topology**. They mediate the inhibitory endocrine and neuromodulatory actions of the peptide hormone **somatostatin** (SST)."
-
SSTR5 binds both somatostatin peptides with ~10-fold higher affinity for SST-28 than SST-14, corroborating the SST-28 preference established in the original cloning papers.
"SSTR5 has been reported to bind both SST forms, with **~10-fold higher affinity for SST-28 than SST-14**, a property often invoked to explain subtype-selective physiological regulation."
-
SSTR activation is canonically Gi/Go-coupled and pertussis-toxin-sensitive, inhibiting adenylyl cyclase and decreasing intracellular cAMP, supporting the core adenylate cyclase-inhibiting GPCR signaling annotation.
"Across subtypes, SSTR activation is canonically **Gi/Go-coupled** (pertussis-toxin-sensitive), producing **inhibition of adenylyl cyclase** and decreased intracellular **cAMP**, often accompanied by reduced Ca2+ signaling and suppression of secretion."
-
Sstr5 functions as an inhibitory GPCR node that restrains secretion in pancreatic islet and pituitary endocrine circuits, supporting roles in insulin secretion regulation.
"Sstr5 acts as an inhibitory GPCR node in paracrine/endocrine circuits where SST restrains secretion (e.g., pancreatic islet hormone release, pituitary hormone output) and can modulate growth-related signaling via phosphatases and MAPK branches."
-
SSTR5 localizes to the plasma membrane as a classical GPCR; rat-specific subcellular microdomain localization was not directly documented in the retrieved evidence.
"The provided evidence base primarily supports **plasma membrane localization** as a classical GPCR and notes family-wide processes such as phosphorylation-dependent desensitization and internalization (general SSTR biology)."
-
Genetic SSTR5 deletion (and selective antagonism) lowers glycemic markers and improves insulin sensitivity, supporting SSTR5's role in glucose homeostasis and insulin secretion regulation.
"genetic SSTR5 deletion and an orally delivered selective antagonist (compound-1) lowered glycemic markers and improved insulin sensitivity indices."
-
A 2024 cryo-EM structure of agonist-bound SSTR5–Gi complexes confirms direct Gi coupling and provides residue-level evidence for the receptor's activation mechanism.
"A major 2024 advance is the **cryo-EM solution of SSTR5–Gi complexes** bound to cyclic peptide agonists **cortistatin-17** and **octreotide** at **2.7–2.9 Å resolution**, enabling residue-level mapping of agonist recognition and activation."